Core Insights - Actinium Pharmaceuticals, Inc. announced compelling preclinical data for ATNM-400, a first-in-class antibody radioconjugate targeting a non-PSMA antigen associated with prostate cancer progression, demonstrating potent therapeutic activity independent of PSMA expression levels [1][4][5] Group 1: Product Overview - ATNM-400 utilizes Actinium-225 (Ac-225) as a potent alpha-emitter, showing superior efficacy compared to existing therapies like enzalutamide and 177Lu-PSMA-617 [1][4] - The product is designed to maintain efficacy in PSMA-low or PSMA-resistant prostate cancer, addressing a significant unmet clinical need [5][8] - Preclinical models indicate that ATNM-400 can overcome resistance to enzalutamide and enhance overall survival when used in combination with ARPI therapies [4][6] Group 2: Market Context - Prostate cancer is the most diagnosed cancer in men, with approximately 1.5 million new cases globally and over 313,000 expected in the U.S. in 2025 [7] - Up to 20% of prostate cancer cases progress to metastatic castration-resistant prostate cancer (mCRPC), a stage with limited treatment options [7] - The ARPI class, including enzalutamide, generated over $10 billion in sales in 2024, highlighting the significant market potential for new therapies like ATNM-400 [7] Group 3: Future Developments - Actinium plans to present ATNM-400 at the 32nd Annual Prostate Cancer Foundation Scientific Retreat on October 23-25, 2025 [2] - The company aims to evaluate ATNM-400 in other solid tumor indications beyond prostate cancer, indicating a broader application of the technology [7][8]